Dr. Chagpar Discusses Benefit of Primary Tumor Surgery in Breast Cancer

Video

In Partnership With:

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses the potential benefit of primary tumor surgery for patients with breast cancer.

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses the potential benefit of primary tumor surgery for patients with breast cancer.

Roughly one-fourth of patients with metastatic breast cancer will present with distant metastatic disease along with their primary tumor, says Chagpar. These patients may benefit from surgery. Retrospective studies have shown that patients with estrogen receptor-positive disease, those with fewer distant metastatic sites, and have bone-only disease benefit from surgery. Chagpar says that there is a suspicion that the benefit observed was due to a selection bias, as these are niche groups of patients.

Chagpar says results from new randomized trials should provide an answer to the question of which patients benefit from surgery of the primary tumor. Previous randomized controlled trials have investigated whether surgery of the primary tumor can improve survival. However, findings were mixed.

Related Videos
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center